Edwards Lifesciences Q2 sales rise 11.9% to $1.53 billion; raises 2025 sales outlook
Edwards Lifesciences reported second-quarter 2025 sales of $1.53 billion, up 11.9% from a year earlier, and adjusted EPS of $0.67. The company raised its full-year 2025 sales growth guidance to 9% to 10% and its adjusted EPS outlook to the high end of $2.40 to $2.50. GAAP net income attributable to Edwards fell to $333.2 million from $366.3 million, partly due to a $47.1 million impairment loss.
Key points
- Q2 sales $1.53 billion, up 11.9%; TAVR sales $1.1 billion, up 8.9%; TMTT sales $134.5 million, up 61.9%
- Full-year 2025 sales guidance raised to 9% to 10%, or $5.9 billion to $6.1 billion; TAVR sales guidance raised to $4.3 billion to $4.5 billion
- Adjusted diluted EPS $0.67 in Q2; full-year adjusted EPS now expected at the high end of $2.40 to $2.50
- Q2 GAAP diluted EPS $0.56 versus $0.61 a year earlier, including a $47.1 million loss on impairment
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 24, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.